New Alzheimer's drug DMB-I enters final testing phase
Disease control
Recruiting now
This study tests whether the drug DMB-I (latrepirdine) can improve thinking and memory in people with mild-to-moderate Alzheimer's dementia. About 450 adults aged 60-90 will take either DMB-I or a placebo daily for 26 weeks, and researchers will compare changes in cognitive test …
Phase: PHASE3 • Sponsor: Bigespas LTD • Aim: Disease control
Last updated May 22, 2026 13:50 UTC